Literature DB >> 24088993

Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury.

Wolfgang G Junger1, Shawn G Rhind, Sandro B Rizoli, Joseph Cuschieri, Andrew J Baker, Pang N Shek, David B Hoyt, Eileen M Bulger.   

Abstract

BACKGROUND: Activation of polymorphonuclear neutrophils (PMNs) is thought to contribute to traumatic brain injury (TBI). Since hypertonic fluids can inhibit PMN activation, we studied whether hypertonic fluid resuscitation can reduce excessive PMN activation in TBI patients.
METHODS: Trauma patients with severe TBI were resuscitated with 250 mL of either 7.5% hypertonic saline (HS; n = 22), HS + 6% dextran-70 (HSD; n = 22), or 0.9% normal saline (NS; n = 39), and blood samples were collected on hospital admission and 12 and 24 h after resuscitation. Polymorphonuclear neutrophil activation (CD11b, CD62L, CD64) and degranulation (CD63, CD66b, CD35) markers and oxidative-burst activity, as well as spontaneous PMN apoptosis were measured by flow cytometry.
RESULTS: Relative to healthy controls, TBI patients showed increased PMN activation and decreased apoptosis of PMNs. In the HS group, but not in the HSD group, markers of PMN adhesion (CD11b, CD64) and degranulation (CD35, CD66b) were significantly lower than those in the NS group. These effects were particularly pronounced 12 h after resuscitation. Treatment with HS and HSD inhibited PMN oxidative burst responses compared with NS-treated patients. Hypertonic saline alone partially restored delayed PMN apoptosis. Despite these differences, the groups did not differ in clinical outcome parameters such as mortality and Extended Glasgow Outcome Scale.
CONCLUSIONS: This study demonstrates that prehospital resuscitation with HS can partially restore normal PMN activity and the apoptotic behavior of PMNs, whereas resuscitation with HSD was largely ineffective. Although the results are intriguing, additional research will be required to translate these effects of HS into treatment strategies that improve clinical outcome in TBI patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24088993      PMCID: PMC3913169          DOI: 10.1097/SHK.0000000000000038

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  50 in total

Review 1.  Osmotic regulation of cell function and possible clinical applications.

Authors:  Alok Shukla; Naoyuki Hashiguchi; Yu Chen; Raul Coimbra; David B Hoyt; Wolfgang G Junger
Journal:  Shock       Date:  2004-05       Impact factor: 3.454

2.  Intracerebral inflammation after human brain contusion.

Authors:  S Holmin; J Söderlund; P Biberfeld; T Mathiesen
Journal:  Neurosurgery       Date:  1998-02       Impact factor: 4.654

3.  Hypertonicity increases cAMP in PMN and blocks oxidative burst by PKA-dependent and -independent mechanisms.

Authors:  Tatjana Orlic; William H Loomis; Amy Shreve; Sachiko Namiki; Wolfgang G Junger
Journal:  Am J Physiol Cell Physiol       Date:  2002-06       Impact factor: 4.249

4.  A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors.

Authors:  Yu Chen; Alok Shukla; Sachiko Namiki; Paul A Insel; Wolfgang G Junger
Journal:  J Leukoc Biol       Date:  2004-04-23       Impact factor: 4.962

5.  Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products.

Authors:  F Colotta; F Re; N Polentarutti; S Sozzani; A Mantovani
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

6.  Effective treatment of refractory intracranial hypertension after traumatic brain injury with repeated boluses of 14.6% hypertonic saline.

Authors:  Ramin Eskandari; Michael R Filtz; Gary E Davis; Robert E Hoesch
Journal:  J Neurosurg       Date:  2013-05-24       Impact factor: 5.115

7.  Clinically relevant hypertonicity prevents stored blood- and lipid-mediated delayed neutrophil apoptosis independent of p38 MAPK or caspase-3 activation.

Authors:  Walter L Biffl; Rachel Carnaggio; Ernest E Moore; David J Ciesla; Jeffrey L Johnson; Christopher C Silliman
Journal:  Surgery       Date:  2003-07       Impact factor: 3.982

8.  Suppression of mitochondria-dependent neutrophil apoptosis with thermal injury.

Authors:  Zhihong Hu; Mohammed M Sayeed
Journal:  Am J Physiol Cell Physiol       Date:  2003-09-17       Impact factor: 4.249

9.  Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial.

Authors:  D James Cooper; Paul S Myles; Francis T McDermott; Lynette J Murray; John Laidlaw; Gregory Cooper; Ann B Tremayne; Stephen S Bernard; Jennie Ponsford
Journal:  JAMA       Date:  2004-03-17       Impact factor: 56.272

10.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.

Authors:  I Vermes; C Haanen; H Steffens-Nakken; C Reutelingsperger
Journal:  J Immunol Methods       Date:  1995-07-17       Impact factor: 2.303

View more
  11 in total

Review 1.  The ebb and flow of fluid (as in resuscitation).

Authors:  K L Mattox
Journal:  Eur J Trauma Emerg Surg       Date:  2014-08-20       Impact factor: 3.693

2.  Inhibition of Neutrophils by Hypertonic Saline Involves Pannexin-1, CD39, CD73, and Other Ectonucleotidases.

Authors:  Yu Chen; Yi Bao; Jingping Zhang; Tobias Woehrle; Yuka Sumi; Stephan Ledderose; Xiaoou Li; Carola Ledderose; Wolfgang G Junger
Journal:  Shock       Date:  2015-09       Impact factor: 3.454

Review 3.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

4.  Chronic Alterations in Systemic Immune Function after Traumatic Brain Injury.

Authors:  Rodney M Ritzel; Sarah J Doran; James P Barrett; Rebecca J Henry; Elise L Ma; Alan I Faden; David J Loane
Journal:  J Neurotrauma       Date:  2018-05-03       Impact factor: 5.269

5.  Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain.

Authors:  Bridgette D Semple; Alpa Trivedi; Kayleen Gimlin; Linda J Noble-Haeusslein
Journal:  Neurobiol Dis       Date:  2014-12-09       Impact factor: 5.996

6.  Hypertonic Saline Primes Activation of the p53-p21 Signaling Axis in Human Small Airway Epithelial Cells That Prevents Inflammation Induced by Pro-inflammatory Cytokines.

Authors:  Fabia Gamboni; Cameron Anderson; Sanchayita Mitra; Julie A Reisz; Travis Nemkov; Monika Dzieciatkowska; Kenneth L Jones; Kirk C Hansen; Angelo D'Alessandro; Anirban Banerjee
Journal:  J Proteome Res       Date:  2016-08-29       Impact factor: 4.466

Review 7.  Bidirectional Brain-Systemic Interactions and Outcomes After TBI.

Authors:  Alan I Faden; James P Barrett; Bogdan A Stoica; Rebecca J Henry
Journal:  Trends Neurosci       Date:  2021-01-22       Impact factor: 13.837

8.  Sera from severe trauma patients with pneumonia and without infectious complications have differential effects on neutrophil biology.

Authors:  B Relja; R Taraki; M P J Teuben; K Mörs; N Wagner; S Wutzler; F Hildebrand; M Perl; I Marzi
Journal:  BMC Pulm Med       Date:  2016-12-01       Impact factor: 3.317

9.  Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study.

Authors:  Jon Hazeldine; David N Naumann; Emma Toman; David Davies; Jonathan R B Bishop; Zhangjie Su; Peter Hampson; Robert J Dinsdale; Nicholas Crombie; Niharika Arora Duggal; Paul Harrison; Antonio Belli; Janet M Lord
Journal:  PLoS Med       Date:  2017-07-18       Impact factor: 11.069

Review 10.  Traumatic Brain Injury and Peripheral Immune Suppression: Primer and Prospectus.

Authors:  Jon Hazeldine; Janet M Lord; Antonio Belli
Journal:  Front Neurol       Date:  2015-11-05       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.